These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14524648)

  • 1. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project.
    Frei CR; Koeller JM; Burgess DS; Talbert RL; Johnsrud MT
    Pharmacotherapy; 2003 Sep; 23(9):1167-74. PubMed ID: 14524648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
    van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
    Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC; Davis CW
    Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals.
    Dudas V; Hopefl A; Jacobs R; Guglielmo BJ
    Ann Pharmacother; 2000 Apr; 34(4):446-52. PubMed ID: 10772428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
    Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
    Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
    Brown RB; Iannini P; Gross P; Kunkel M
    Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia.
    Burgess DS; Lewis JS
    Clin Ther; 2000 Jul; 22(7):872-8. PubMed ID: 10945513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation.
    Madaras-Kelly KJ; Burk M; Caplinger C; Bohan JG; Neuhauser MM; Goetz MB; Zhang R; Cunningham FE;
    J Hosp Med; 2016 Dec; 11(12):832-839. PubMed ID: 27527659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia.
    Han X; Zhou F; Li H; Xing X; Chen L; Wang Y; Zhang C; Liu X; Suo L; Wang J; Yu G; Wang G; Yao X; Yu H; Wang L; Liu M; Xue C; Liu B; Zhu X; Li Y; Xiao Y; Cui X; Li L; Purdy JE; Cao B;
    BMC Infect Dis; 2018 Apr; 18(1):192. PubMed ID: 29699493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals.
    Nie XM; Li YS; Yang ZW; Wang H; Jin SY; Jiao Y; Metersky ML; Huang Y
    Clin Microbiol Infect; 2018 Jun; 24(6):658.e1-658.e6. PubMed ID: 28970157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-acquired pneumonia and do not resuscitate orders.
    Marrie TJ; Fine MJ; Kapoor WN; Coley CM; Singer DE; Obrosky DS
    J Am Geriatr Soc; 2002 Feb; 50(2):290-9. PubMed ID: 12028211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia.
    Malone DC; Shaban HM
    Ann Pharmacother; 2001 Oct; 35(10):1180-5. PubMed ID: 11675841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
    Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
    Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
    Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
    J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals.
    Marras TK; Jamieson L; Chan CK
    Can Respir J; 2004 Mar; 11(2):131-7. PubMed ID: 15045044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.
    Shefet D; Robenshtock E; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2005 Apr; (2):CD004418. PubMed ID: 15846713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.